2-Amino-1-(4-propan-2-ylpiperazin-1-yl)ethanone

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Amino-1-(4-propan-2-ylpiperazin-1-yl)ethanone
• 化学式: C₉H₁₉N₃O
• 分子量: 185.269
• InChiKey: XDMDSQSMNHEMBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  49.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-Amino-1-(4-propan-2-ylpiperazin-1-yl)ethanone 在 N-甲基吗啉 、 盐酸 、 甲烷 、 氯甲酸异丁酯 、 氯甲酸三氯甲酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 26.0h， 生成 quinoline-4-carboxylic acid [(S)-1-((S)-1-{(S)-1-[2-(4-isopropyl-piperazin-1-yl)-2-oxo-ethylaminooxalyl]-2-methylpropylcarbamoyl}ethylcarbamoyl)-2,2-dimethylpropyl]amide trifluoroacetate salt
  参考文献：
  名称：

  The Discovery of Potent, Selective, and Reversible Inhibitors of the House Dust Mite Peptidase Allergen Der p 1: An Innovative Approach to the Treatment of Allergic Asthma

  摘要：

  Blocking the bioactivity of allergens is conceptually attractive as a small-molecule therapy for allergic diseases but has not been attempted previously. Group 1 allergens of house dust mites (HDM) are meaningful targets in this quest because they are globally prevalent and clinically important triggers of allergic asthma. Group 1 HDM allergens are cysteine peptidases whose proteolytic activity triggers essential steps in the allergy cascade. Using the HDM allergen Der p 1 as an archetype for structure-based drug discovery, we have identified a series of novel, reversible inhibitors. Potency and selectivity were manipulated by optimizing drug interactions with enzyme binding pockets, while variation of terminal groups conferred the physicochemical and pharmacokinetic attributes required for inhaled delivery. Studies in animals challenged with the gamut of HDM allergens showed an attenuation of allergic responses by targeting just a single component, namely, Der p 1. Our findings suggest that these inhibitors may be used as novel therapies for allergic asthma.

  DOI：

  10.1021/jm501102h

文献信息

• Design and Synthesis of New Pyrazole‐Based Heterotricycles and their Derivatization by Automated Library Synthesis
  作者：Prisca Fricero、Laurent Bialy、Werngard Czechtizky、María Méndez、Joseph P. A. Harrity

  DOI：10.1002/cmdc.202000187

  日期：2020.9.3

  distinct 5‐6‐6‐ and 5‐7‐6‐fused tricyclic compounds. This chemistry is not only amenable to single compound synthesis, but also to high‐throughput experimentation. It gives easy access to diverse compound arrays with various physicochemical and ADME profiles by fully automated library synthesis. The combination of the high‐throughput experimentation with rapid testing of the compounds in an integrated

  具有正交功能的小分子杂环化合物有可能提供多种结构基序，从而有助于药物发现。这项工作着重说明了易于组装的N-羟乙基吡唑三氟硼酸酯如何快速提供结构上独特的5-6-6-6和5-7-6稠合的三环化合物。这种化学方法不仅适用于单一化合物的合成，而且适用于高通量实验。通过全自动库合成，可以轻松访问具有各种物理化学和ADME谱的各种化合物阵列。高通量实验与在集成的物理化学和ADME分析工作流程中对化合物的快速测试相结合，可以加快药物发现项目中新型先导化合物的设计。
• IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
  申请人：Marmsater Fredrik P.

  公开号：US20100144751A1

  公开（公告）日：2010-06-10

  Compounds of Formula (I): are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class (3) and class (5) receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1.

  化学式（I）的化合物是受体酪氨酸激酶抑制剂，可用于治疗由类（3）和类（5）受体酪氨酸激酶介导的疾病。该发明的特定化合物也被发现是Pim-1的抑制剂。
• PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT
  申请人：Babaoglu Kerim

  公开号：US20120003215A1

  公开（公告）日：2012-01-05

  The invention provides compounds of Formula I or Formula II: or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.

  本发明提供了公式I或公式II的化合物：或其药学上可接受的盐或酯，如本文所述。这些化合物及其组合物对于治疗Pneumovirinae病毒感染非常有用。提供的化合物，组合物和方法特别适用于治疗人类呼吸道合胞病毒感染。
• TETRACYCLIC INHIBITORS OF JANUS KINASES
  申请人：Rodgers James D.

  公开号：US20090215766A1

  公开（公告）日：2009-08-27

  The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.

  本发明提供了一种可以调节Janus激酶活性的化合物，这些化合物可用于治疗与Janus激酶活性相关的疾病，例如免疫相关疾病和癌症。
• Pyrimido-pyridazinone compounds and methods of use thereof
  申请人：Asana Biosciences, LLC

  公开号：US10183944B2

  公开（公告）日：2019-01-22

  The present application provides novel pyrimido-pyridazinone compounds and methods for preparing and using these compounds. These compounds are useful in treating inflammation in patients by administering one or more of the compounds to a patient. In one embodiment, the novel pyrimido-pyridazinone compound is of Formula (I) and R1 and R2 are defined herein.

  本申请提供了新型嘧啶哒嗪酮化合物以及制备和使用这些化合物的方法。通过向患者施用一种或多种化合物，这些化合物可用于治疗患者的炎症。在一个实施方案中，新型嘧啶基哒嗪酮化合物为式(I)，R1和R2在此定义。